627097-32-9

Upstream product

• 627097-31-8 ethyl 2-(3-aminocarbonylmethylphenoxy)-2-methylpropionate 
• 600-00-0 ethyl 2-bromoisobutyrate 
• 588713-66-0 ethyl 2-(3-bromophenoxy)-2-methylpropanoate 
• 909114-15-4 C₂₂H₂₁NO₅ 
• 591-20-8 3-Bromophenol 
• 909114-16-5 C₂₂H₂₃NO₅ 
• 851508-11-7 ethyl (E)-2-methyl-2-(3-(2-nitrovinyl)phenoxy)propanoate 

Downstream Products

• 627097-33-0 Ethyl 2-[3-[2-(N-benzoxazol-2-yl)aminoethyl]phenoxy]-2-methylpropionate 
• 909112-82-9 ethyl 2-methyl-2-(3-{2-[4-methyl-3,5-dioxo-2-(4,4,4-trifluoro-butyl)-2,3,4,5-tetrahydro-[1,2,4]triazin-6-ylamino]-ethyl}-phenoxy)-propionate 

Relevant academic research and scientific papers

1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy

The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1/s

Phenyl derivatives, their manufacture and use as pharmaceutical agents

This invention relates to compounds of the formula wherein one of R5, R6 and R7 is and X1, X2, Y1 to Y4, R1 to R13 and m and n are defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

Benzoxazole compound and pharmaceutical composition containing the same

The present invention is directed to a benzoxazole compound represented by the following formula (1): (wherein R1represents an alkyl group, a C6-10aryl-C1-8alkyl group, etc.; each of R2and R3, which a